Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 11/20 | 0.37 |
| ▸ | BCHE | P06276 | 10/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | CPT2 | P23786 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 2/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22021658 | 0.88 | EPHX2 (0.41) | EPHX2ACHEBCHECHRM2CHRM1 | |
| SCHEMBL22021680 | 0.88 | EPHX2 (0.41) | EPHX2ACHEBCHECHRM2CHRM1 | |
| SCHEMBL22021685 | 0.88 | EPHX2 (0.41) | EPHX2ACHEBCHECHRM2CHRM1 | |
| SCHEMBL22021900 | 0.87 | EPHX2 (0.36) | EPHX2ACHEBCHEFFAR1CPT2 | |
| SCHEMBL22166535 | 0.85 | EPHX2 (0.53) | EPHX2FFAR1TDP1CNR1ALDH1A1 | |
| SCHEMBL22166531 | 0.85 | EPHX2 (0.53) | EPHX2FFAR1TDP1CNR1ALDH1A1 | |
| SCHEMBL23639935 | 0.84 | EPHX2 (0.34) | EPHX2ACHEBCHE | |
| SCHEMBL22166526 | 0.83 | EPHX2 (0.40) | EPHX2ACHEBCHECNR1ALDH1A1 | |
| SCHEMBL22021691 | 0.83 | EPHX2 (0.50) | EPHX2CNR1ALDH1A1ESR1ESR2 | |
| SCHEMBL26493973 | 0.83 | EPHX2 (0.40) | EPHX2ACHEBCHECNR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117885-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200299264-A1 | COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200157078-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117885-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ESR2, ESRRG, ESR1 | EPHX2 896/4885ACHE 1667/4885BCHE 1192/4885 |
| US-20200157078-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ESR2, ESRRG, ESR1 | EPHX2 951/4885ACHE 2330/4885BCHE 1505/4885 |
| US-20200299264-A1 | COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ESR2, ESRRG, ESR1 | EPHX2 896/4885ACHE 1667/4885BCHE 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.